» Articles » PMID: 29207194

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κB

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2017 Dec 6
PMID 29207194
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Highly active antiretroviral therapy (HAART) is very effective in suppressing human immunodeficiency virus type 1 (HIV‑1) replication. However, the treatment is required to be administered for the remainder of an individual's lifetime due to latent HIV‑1 reservoirs. The 'shock‑and‑kill' strategy, which involves using agents to reactivate latent HIV‑1 and subsequently killing latently infected cells in the presence of HAART, was recently proposed. Unfortunately, no agents have currently demonstrated an ability to reactivate latent HIV‑1 in vivo in the absence of toxicity. Therefore, the identification of novel latency activators is required. In order to identify a potential novel agent, the present study investigated the effect of quercetin on latent HIV‑1 reactivation using an established model of HIV‑1 latency. As a marker for reactivation of HIV‑1 in C11 Jurkat cells, the expression of green fluorescent protein, controlled by HIV‑1 long terminal repeat, was observed by fluorescence microscopy. The results of the present study demonstrated that quercetin effectively reactivated latent HIV‑1 gene expression alone, and led to synergistic reactivation when combined with prostratin or valproic acid. In addition, the present study provides evidence that quercetin may reactivate HIV‑1 expression by inducing nuclear factor‑κB nuclear translocation, and that the toxicity of quercetin is lower when compared with various additional activators of HIV‑1. Combined, the results of the present study indicate that quercetin may be an effective agent to disrupt HIV‑1 latency and may be useful in future eradication strategies.

Citing Articles

The Role of Quercetin, a Flavonoid in the Management of Pathogenesis Through Regulation of Oxidative Stress, Inflammation, and Biological Activities.

Alharbi H, Alshebremi M, Babiker A, Rahmani A Biomolecules. 2025; 15(1).

PMID: 39858545 PMC: 11763763. DOI: 10.3390/biom15010151.


Mechanisms and efficacy of small molecule latency-promoting agents to inhibit HIV reactivation ex vivo.

Janssens J, Kim P, Kim S, Wedrychowski A, Kadiyala G, Hunt P JCI Insight. 2024; 9(19).

PMID: 39163135 PMC: 11466185. DOI: 10.1172/jci.insight.183084.


Emerging roles of senolytics/senomorphics in HIV-related co-morbidities.

Kaur G, Rahman M, Shaikh S, Panda K, Chinnapaiyan S, Santiago Estevez M Biochem Pharmacol. 2024; 228():116179.

PMID: 38556028 PMC: 11410549. DOI: 10.1016/j.bcp.2024.116179.


Potential Targets and Mechanisms of Bitter Almond-Licorice for COVID-19 Treatment Based on Network Pharmacology and Molecular Docking.

Hong Q, Shang X, Wu Y, Nie Z, He B Curr Pharm Des. 2023; 29(33):2655-2667.

PMID: 38018195 PMC: 10788922. DOI: 10.2174/0113816128265009231102063840.


Phenolic Compounds in spp. and Their Potential Therapeutic Effects on H1N1, HBV, HCV, and HIV: A Review.

Fredsgaard M, Kaniki S, Antonopoulou I, Chaturvedi T, Thomsen M Molecules. 2023; 28(14).

PMID: 37513186 PMC: 10384198. DOI: 10.3390/molecules28145312.